The spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binds its cellular receptor, the angiotensin-converting enzyme 2 (ACE2), expressed in nasal and bronchial epithelial cells, pneumocytes and brain vascular endothelium.[5] Endotheliopathy has been recognized as one of the main pathogenic mechanism in COVID-19, including cerebral arteries involvement [3, 6], that may be responsive to high-dose glucocorticoids [7]. The gene discussed is ACE2; the disease is COVID-19.